( A ) Introducing bone marrow cells producing ADA into cells at early embryonic stages
( B ) Periodic infusion of genetically engineered lymphocytes having functional ADA cDNA
( C ) Enzyme replacement therapy
( D ) Administering adenosine deaminase activators